Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarpogrelate vs Aspirin in Cerebral Infarction (S-ACCESS)
NCT00129805Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jan 2001
- Primary completion
- Sep 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sarpogrelate in cerebral infarction (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Recurrence of cerebral infarction. Started Jan 2001; status: completed.
02
Drugs
sarpogrelate
03
Conditions
cerebral infarction
Beyond the preview
Go deeper on NCT00129805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129805.